Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Antiretroviral neurotoxicity.

Robertson K, Liner J, Meeker RB.

J Neurovirol. 2012 Oct;18(5):388-99. doi: 10.1007/s13365-012-0120-3. Epub 2012 Jul 19.

2.

HIV-associated neurological disorders: a guide to pharmacotherapy.

Tan IL, McArthur JC.

CNS Drugs. 2012 Feb 1;26(2):123-34. doi: 10.2165/11597770-000000000-00000. Review.

PMID:
22201342
3.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

HIV-1-associated central nervous system dysfunction.

Krebs FC, Ross H, McAllister J, Wigdahl B.

Adv Pharmacol. 2000;49:315-85. Review.

PMID:
11013768
6.

Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.

Wright EJ.

Curr Opin HIV AIDS. 2009 Sep;4(5):447-52. doi: 10.1097/COH.0b013e32832dd0c2. Review.

PMID:
20048710
8.

CSF penetration by antiretroviral drugs.

Eisfeld C, Reichelt D, Evers S, Husstedt I.

CNS Drugs. 2013 Jan;27(1):31-55. doi: 10.1007/s40263-012-0018-x. Review.

PMID:
23160938
9.

Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway.

Nath S, Bachani M, Harshavardhana D, Steiner JP.

J Neurovirol. 2012 Dec;18(6):445-55. doi: 10.1007/s13365-012-0122-1. Epub 2012 Aug 11.

PMID:
22886603
10.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
11.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

12.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

13.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
14.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Mofenson LM; Centers for Disease Control and Prevention, U.S. Public Health Service Task Force.

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

15.

HIV, antiretroviral therapies, and the brain.

Liner KJ 2nd, Ro MJ, Robertson KR.

Curr HIV/AIDS Rep. 2010 May;7(2):85-91. doi: 10.1007/s11904-010-0042-8. Review.

PMID:
20425562
16.

Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.

Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, McCutchan JA, Masliah E, Ellis RJ.

J Neurovirol. 2006 Apr;12(2):100-7.

PMID:
16798671
17.
18.

Ketone bodies protection against HIV-1 Tat-induced neurotoxicity.

Hui L, Chen X, Bhatt D, Geiger NH, Rosenberger TA, Haughey NJ, Masino SA, Geiger JD.

J Neurochem. 2012 Jul;122(2):382-91. doi: 10.1111/j.1471-4159.2012.07764.x. Epub 2012 May 17.

20.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk